Table 1 Basic characteristics of the included studies
Author, Year | Country | Study design | Diagnose standard | DS year | Study period | sample size | Male/ Female | Ages | FVC% predit | Measurement instrument | Ethic |
|---|---|---|---|---|---|---|---|---|---|---|---|
Duke et al. 2024 [31] | USA | prospective cohort | chest computed tomography | NA | 2018.9-2021.8 | 65 | 51/14 | 72.0 | 73.9 | CRQ | YES |
Sridhar et al. 2024 [32] | USA | prospective cohort | ATS/ERS/JRS | NR | 2016–2018 | 70 | 47/23 | 70.4 | 66.5 | SGRQ | YES |
Cox et al. 2023 [33] | Australia | prospective cohort | ATS/ERS/JRS/ALAT | 2018 | 2018.8-2019.10 | 162 | 99/63 | 73.8 | 87.6 | EQ-5D AQoL-8D SGRQ | YES |
Rautajoki et al. 2023 [34] | Finland | prospective cohort | ATS/ERS/JRS/ALAT | 2018 | 2015.4-2017.10 | 247 | 263/84 | 74.3 | 82.9 | 15D | YES |
Saari et al. 2023 [35] | Finland | case control | HRCT and transbronchial lung biopsy | NA | 2015.1-2021.12 | 68 | 39/29 | 67.4 | 79.95 | LCQ | YES |
Veit et al. 2023 [36] | Germany | prospective cohort | ATS/ERS | 2013 | 2017.7-2018.8 | 13 | 10/3 | 65.3 | 68.5 | SGRQ KBILD | YES |
Zheng et al. 2023 [37] | Australia | prospective cohort | ATS/ERS/JRS/ALAT | 2018 | 2018.8-2019.12 | 157 | 95/62 | 74.0 | 79.9 | HSUs | YES |
Park et al. 2022 [38] | South Korea | prospective cohort | ATS/ERS/JRS/ALAT | 2015 | 2017.6-2018.9 | 70 | 52/18 | 67.9 | 77.25 | EQ-5D SGRQ CQLQ | YES |
Phua et al. 2022 [39] | Singapore | cross-sectional | ATS/ERS | 2013 | 2019.12-2022.1 | 27 | NR | NR | 78.1 | EQ-5D KBILD | YES |
Reinaldo et al. 2022 [40] | Brazil | cross-sectional | pulmonary function with lung biopsy or HRCT | NA | NR | 27 | 19/8 | 60.7 | 51.10 | SGRQ | YES |
Scallan et al. 2022 [41] | USA | cross-sectional | ATS/ERS/JRS/ALAT | 2018 | 2019.9.-2019.10 | 100 | 67/33 | 71.2 | 70.5 | EQ-5D KBILD | YES |
Wuyts et al. 2022 [42] | multi-country | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2013.10-2016.1 | 277 | 213/64 | 69.6 | 80.6 | EQ-5D SGRQ | YES |
Bloem et al. 2021 [43] | Netherlands | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2018.5-2019.3 | 61 | 47/14 | 73.7 | 82.8 | EQ-5D | YES |
Chen et al. 2021 [44] | Canada | prospective cohort | ATS/ERS/JRS/ALAT | 2018 | 2015.1-2020.3 | 539 | 413/126 | 69.0 | 76 | EQ-5D SGRQ | YES |
Cox et al. 2021 [45] | Australia | prospective cohort | ATS/ERS/JRS/ALAT | 2018 | 2018.8-2019.10 | 155 | 99/56 | 74.0 | 87.5 | EQ-5D | YES |
Ebihara et al. 2021 [46] | Japan | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2014.7-2017.7 | 27 | 21/6 | 76.1 | 72.0 | SGRQ | YES |
Gao et al. 2021 [47] | Sweden | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2014.9-2020.4 | 662 | 490/172 | 72.8 | 72.4 | KBILD | YES |
Kanjrawi et al. 2021 [48] | Australia | prospective cohort | Medical records | NA | 2019.8-2019.10 | 27 | 19/8 | 71.0 | 77 | EQ-5D KBILD | YES |
Machado et al. 2021 [49] | Germany | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2012.3-2017.10 | 98 | 84/14 | 68.0 | 64 | SF-36 | YES |
Prior et al. 2021 [50] | Denmark | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2016.8-2018.3 | 150 | 122/28 | 72.9 | 87.2 | SGRQ-I | YES |
Behr et al. 2020 [51] | Germany | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2012.12-2018.12 | 588 | 476/112 | 69.8 | 68.6 | EQ-5D | YES |
Bloem et al. 2020 [52] | Netherlands | cross-sectional | ATS/ERS/JRS/ALA | 2011 | 2018.5-2019.3 | 59 | 45/14 | 73.7 | 83.2 | EQ-5D QoL-RIQ | YES |
Case et al. 2020 [53] | USA | retrospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2014.6-2017.10 | 662 | 496/166 | 70.0 | 69.8 | EQ-5D SGRQ SF-12 | YES |
Durheim et al. 2020 [54] | Norway | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2017.9-2018.10 | 57 | 41/16 | 71.0 | 73 | EQ-5D SGRQ KBILD LCQ | YES |
Leuschner et al. 2020 [55] | Germany | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2012.11-2019.12 | 1009 | 814/195 | 75.3 | 67.89 | EQ-5D SGRQ | YES |
Moor et al. 2020 [56] | Netherlands | RCT | ATS/ERS/JRS/ALAT | 2018 | 2018.1-2019.1 | 46 | 39/7 | 68.6 | 82.6 | EQ-5D KBILD PESaM | YES |
O’Brien et al. 2020 [57] | USA | Cross-Sectional | ATS/ERS/JRS/ALAT | 2011 | 2014.6-2018.7 | 859 | 639/220 | 70.0 | 69.7 | EQ-5D SGRQ SF-12 | YES |
Prior et al. 2020 [58] | Denmark | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2016.8-2019.3 | 150 | 122/28 | 72.9 | 87.2 | SGRQ KBILD SGRQ-I | YES |
Tzouvelekis et al. 2020 [59] | Greece | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2016–2017 | 98 | 80/18 | 70.8 | 77.0 | SGRQ KBILD | YES |
Eken et al. 2019 [60] | Turkey | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2016.10-2016.10 | 40 | 31/9 | 65.1 | 86.60 | SGRQ | YES |
Kalafatis et al. 2019 [61] | Sweden | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2014.9-2017.12 | 384 | 250/98 | 71.8 | 70.2 | KBILD | YES |
Pan et al. 2019 [62] | China | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2014.1-2015.8 | 20 | 14/6 | 58.3 | NR | SGRQ ATAQ-IPF | YES |
Prior et al. 2019 [63] | Denmark | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2016.8-2018.3 | 150 | 122/28 | 72.9 | 87.2 | KBILD SF-36 SGRQ-I | YES |
Capparelli et al. 2018 [64] | Argentina | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2026.01-2017.01 | 23 | 18/5 | 71.9 | 68.9 | SGRQ-I | YES |
Mavroudi et al. 2018 [65] | Greece | case control | ATS/ERS | 2000 | 2013.11-2015.11 | 19 | 11/8 | 69.8 | 75.6 | SF-36 | YES |
Nolan et al. 2018 [66] | UK | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2015.01-2015.12 | 65 | 58/7 | 72.0 | 73.2 | KBILD | YES |
Wuyts et al. 2018 [67] | multi-country | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2013.10-2016.1 | 277 | 213/64 | 69.6 | 80.6 | EQ-5D SGRQ | YES |
Furukawa et al. 2017 [68] | Japan | Retrospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2007.5-2012.12 | 182 | 155/27 | 65.6 | 79.7 | SGRQ | YES |
Kreuter et al. 2017 [69] | Germany | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | NR | 623 | 481/142 | 69.6 | 67.5 | EQ-5D SGRQ | YES |
Magnani et al. 2017 [70] | Italy | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2015.1-2015.6 | 18 | 8/10 | 66.5 | NR | PGWBI | NR |
Matsuda et al. 2017 [71] | Japan | retrospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2009.4-2013.3 | 121 | 99/22 | 66.8 | 81.1 | SGRQ | YES |
Matsuda et al. 2017 [72] | Japan | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2011.7-2014.10 | 106 | 90/16 | 67.1 | 81.9 | SGRQ | YES |
Natalini et al. 2017 [73] | USA | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2010.3-2015.9 | 50 | 39/11 | 70.8 | 70.3 | SF-36 | YES |
Sokai et al. 2017 [74] | Japan | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2013.4-2014.10 | 52 | 44/8 | 72.0 | 86.1 | SF-36 SGRQ-I | YES |
Wapenaar et al. 2017 [75] | multi-country | prospective cohort | ATS/ERS | 2000 | 2013.12-2016.4 | 108 | 84/24 | 70.5 | 72.5 | EQ-5D SGRQ KBILD | YES |
Atkins et al. 2016 [76] | UK | cross-sectional | ATS/ERS/JRS/ALAT | 2011 | 2012.9-2014.3 | 77 | 59/18 | 76.4 | 84.3 | EQ-5D SGRQ KBILD | YES |
Bahmer et al. 2016 [77] | Germany | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2013.1-2013.10 | 48 | 36/12 | 67.1 | 75.4 | SGRQ SF-12 | YES |
Kotecha et al. 2016 [78] | UK | prospective cohort | ATS/ERS/JRS/ALAT | 2011 | 2013.1-2014.3 | 75 | 58/17 | 76.4 | 83.6 | SGRQ | YES |
Lubin et al. 2014 [79] | USA | prospective cohort | ATS/ERS | 2000 | 2010.1-2012.8 | 102 | 76/26 | 70.0 | 70.0 | SF-36 | YES |
Nishiyama et al. 2012 [80] | Japan | retrospective cohort | ATS/ERS | 2000 | 2000.4-2005.7 | 87 | 77/10 | 66.3 | 75 | SGRQ | YES |
Noth et al. 2012 [81] | USA | RCT | ATS/ERS/JRS/ALAT | 22,011 | 2009.12-2011.4 | 145 | 106/39 | 66.9 | 58.79 | EQ-5D SGRQ SF-36 | YES |
Swigris et al. 2012 [82] | USA | retrospective cohort | ATS/ERS | 2005 | NR | 180 | 83/97 | 69.0 | 56.8 | SGRQ SF-36 | NR |
Elfferich et al. 2011 [83] | Netherlands | cross-sectional | Medical records | NA | 2007.10 | 49 | 31/18 | 63.1 | 82.9 | WHOQOL-100 | YES |
King et al. 2011 [84] | multi-country | RCT | ATS/ERS | 2000 | 2007.1-2008.10 | 407 | 296/111 | 63.8 | 74.9 | EQ-5D SF-36 | YES |
Jones et al. 2011 [85] | UK | case control | ATS/ERS | 2002 | NR | 27 | 17/10 | 71.7 | 80.4 | LCQ | YES |
Verma et al. 2011 [86] | Canada | cross-sectional | ATS/ERS | 2000 | 2003.10-2008.3 | 137 | 90/47 | 59.4 | 61.7 | SGRQ SF-36 | YES |
Han et al. 2010 [87] | USA | cross-sectional | ATS/ERS | 2000 | 2003-2009.1 | 221 | 147/74 | 63.3 | 62.77 | SGRQ SF-12 | YES |
Key et al. 2010 [88] | UK | cross-sectional | ATS/ERS | 2002 | 2001–2007 | 19 | 14/5 | 70.8 | 78.5 | LCQ | YES |
Swigris et al. 2010 [89] | USA | prospective cohort | ATS/ERS | 2000 | NR | 95 | 82/13 | 69.3 | 65 | ATAQ-IPF | NR |
Zisman et al. 2010 [90] | USA | RCT | ATS/ERS | 2000 | 2007.9-2009.3 | 89 | 75/14 | 69.8 | 54.89 | EQ-5D SGRQ SF-36 | YES |
Krishnan et al. 2008 [91] | USA | cross-sectional | ATS/ERS | 2000 | NR | 41 | 22/19 | 67.7 | 68.9 | SF-36 | YES |
Peng et al. 2008 [92] | China | cross-sectional | ATS/ERS | 2000 | 2002.1-2007.5 | 68 | 54/14 | 64.0 | 66 | SGRQ | YES |
Tomioka et al. 2007 [93] | Japan | cross-sectional | ATS/ERS | 2000 | 2000.3-2005.12 | 46 | 32/14 | 69.9 | 71 | SF-36 | YES |
Zimmermann et al. 2007 [94] | Brazil | cross-sectional | ATS/ERS | 2000 | NR | 20 | 12/8 | 61.5 | 70.4 | SGRQ SF-36 | NR |
Nishiyama et al. 2005 [95] | Japan | prospective cohort | ATS/ERS | 2000 | 2000.1-2002.12 | 41 | 35/6 | 64.0 | 76.6 | SGRQ | NR |
Tzanakis et al. 2005 [96] | Greece | cross-sectional | ATS/ERS | 2000 | 1994.1-1999.7 | 25 | 21/4 | 66.0 | 68.8 | SGRQ | YES |
Baddini et al. 2002 [97] | Brazil | cross-sectional | Lung biopsy and CT | NA | NR | 30 | 18/12 | 58.6 | 61.9 | SF-36 | YES |
De Vries et al. 2001 [98] | Netherlands | cross-sectional | ATS/ERS | 2000 | NR | 41 | 15/26 | 63.5 | NR | WHOQOL-100 | NR |